| Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia JC Byrd, RR Furman, SE Coutre, IW Flinn, JA Burger, KA Blum, B Grant, ... New England Journal of Medicine 369 (1), 32-42, 2013 | 2859 | 2013 |
| Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia JA Burger, A Tedeschi, PM Barr, T Robak, C Owen, P Ghia, O Bairey, ... New England Journal of Medicine 373 (25), 2425-2437, 2015 | 1847 | 2015 |
| CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment JA Burger, TJ Kipps Blood 107 (5), 1761-1767, 2006 | 1507 | 2006 |
| Mesenchymal precursor cells in the blood of normal individuals NJ Zvaifler, L Marinova-Mutafchieva, G Adams, CJ Edwards, J Moss, ... Arthritis Research & Therapy 2, 1-12, 2000 | 1144 | 2000 |
| Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell–derived factor-1 JA Burger, N Tsukada, M Burger, NJ Zvaifler, M Dell'Aquila, TJ Kipps Blood, The Journal of the American Society of Hematology 96 (8), 2655-2663, 2000 | 1026 | 2000 |
| Three-year follow-up of treatment-naive and previously treated patients with CLL and SLL receiving single-agent ibrutinib JC Byrd, RR Furman, SE Coutre, JA Burger, KA Blum, M Coleman, ... Blood, The Journal of the American Society of Hematology 125 (16), 2497-2506, 2015 | 883 | 2015 |
| The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo S Ponader, SS Chen, JJ Buggy, K Balakrishnan, V Gandhi, WG Wierda, ... Blood, The Journal of the American Society of Hematology 119 (5), 1182-1189, 2012 | 802 | 2012 |
| Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial S O'Brien, RR Furman, SE Coutre, JP Sharman, JA Burger, KA Blum, ... The lancet oncology 15 (1), 48-58, 2014 | 731 | 2014 |
| The microenvironment in mature B-cell malignancies: a target for new treatment strategies JA Burger, P Ghia, A Rosenwald, F Caligaris-Cappio Blood, The Journal of the American Society of Hematology 114 (16), 3367-3375, 2009 | 704 | 2009 |
| The phosphoinositide 3′-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia J Hoellenriegel, SA Meadows, M Sivina, WG Wierda, H Kantarjian, ... Blood, The Journal of the American Society of Hematology 118 (13), 3603-3612, 2011 | 688 | 2011 |
| Chronic lymphocytic leukemia B cells express functional CXCR4 chemokine receptors that mediate spontaneous migration beneath bone marrow stromal cells JA Burger, M Burger, TJ Kipps Blood, The Journal of the American Society of Hematology 94 (11), 3658-3667, 1999 | 684 | 1999 |
| CXCR4 antagonists: targeting the microenvironment in leukemia and other cancers JA Burger, A Peled Leukemia 23 (1), 43-52, 2009 | 557 | 2009 |
| Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study JA Burger, PM Barr, T Robak, C Owen, P Ghia, A Tedeschi, O Bairey, ... Leukemia 34 (3), 787-798, 2020 | 542 | 2020 |
| Ibrutinib and venetoclax for first-line treatment of CLL N Jain, M Keating, P Thompson, A Ferrajoli, J Burger, G Borthakur, ... New England Journal of Medicine 380 (22), 2095-2103, 2019 | 542 | 2019 |
| Final analysis from RESONATE: up to six years of follow‐up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma T Munir, JR Brown, S O'Brien, JC Barrientos, PM Barr, NM Reddy, ... American journal of hematology 94 (12), 1353-1363, 2019 | 508 | 2019 |
| ICOS deficiency is associated with a severe reduction of CXCR5+ CD4 germinal center Th cells L Bossaller, J Burger, R Draeger, B Grimbacher, R Knoth, A Plebani, ... The Journal of Immunology 177 (7), 4927-4932, 2006 | 502 | 2006 |
| Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience S O’Brien, RR Furman, S Coutre, IW Flinn, JA Burger, K Blum, J Sharman, ... Blood, The Journal of the American Society of Hematology 131 (17), 1910-1919, 2018 | 460 | 2018 |
| Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation F Ravandi, ML Alattar, MR Grunwald, MA Rudek, T Rajkhowa, MA Richie, ... Blood, The Journal of the American Society of Hematology 121 (23), 4655-4662, 2013 | 454 | 2013 |
| Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study JA Burger, MJ Keating, WG Wierda, E Hartmann, J Hoellenriegel, ... The Lancet Oncology 15 (10), 1090-1099, 2014 | 439 | 2014 |
| Targeting B cell receptor signalling in cancer: preclinical and clinical advances JA Burger, A Wiestner Nature Reviews Cancer 18 (3), 148-167, 2018 | 437 | 2018 |
Thomas J. KippsProfessor of Medicine, UC San Diegoยืนยันอีเมลแล้วที่ ucsd.edu
